The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2

Cancer Immunology, Immunotherapy

Volumn 56, Issue 3, 2007, Pages 287-301

  Mitchell, Malcolm S ^a   Lund, Teri A ^a   Sewell, Andrew K ^b   Marincola, Francesco M ^c   Paul, Elyse ^a   Schroder, Kim ^d   Wilson, Darcy B ^d   Kan Mitchell, June ^a,e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Agonist peptide; Cancer; CTL epitope; Immunotherapy

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 2; MUCIN 2; PEPTIDE LIBRARY; PROTEIN; PROTEIN P15; PROTEIN P29; T LYMPHOCYTE RECEPTOR; TETRAMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DONOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MUTATION; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; WILD TYPE;

ADULT; CA-15-3 ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; REFERENCE VALUES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845918545     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0191-1     Document Type: Article

References (55)

1. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M (2002) MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7:209-221
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
3. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820-12823
4. Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S, Kanz L, Buhring HJ, Brugger W (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61:6846-6850
5. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286-15293
6. Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J (1990) Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265:5573-5578
7. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783-2792
8. Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO (2002) Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 97:660-667
9. Schmielau J, Nalesnik MA, Finn OJ (2001) Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 7:933s-939s
10. Musselli C, Livingston PO, Ragupathi G (2001) Keyhole limpet hemocyanin conjugate vaccines against cancer: the memorial sloan kettering experience. J Cancer Res Clin Oncol 127(Suppl 2):R20-R26
11. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF (1997) Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159:5211-5218
12. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317
13. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108
14. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH (1992) HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255:1264-1266
15. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:452-458
16. Correa I, Plunkett T, Coleman J, Galani E, Windmill E, Burchell JM, Taylor-Papdimitriou J (2005) Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 115:760-768
17. Riddell SR (2004) Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 200:1533-1537
18. Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M, Bereta M (2004) The HIV-1 HLA-A2-SLYNT-VATL is a help-independent CTL epitope. J Immunol 172:5249-5261
19. Kan-Mitchell J, Bajcz M, Schaubert KL, Price DA, Brenchley JM, Asher TE, Douek DC, Ng HL, Yang OO, Rinaldo CR, Benito JM, Bisikirska B, Hegde R, Marincola FM, Boggiano C, Wilson D, Abrams J, Blondelle SE, Wilson DB (2006) Degeneracy and repertoire of the human HIV-1 Gag p17(77-85) CTL response. J Immunol 176:6690-6701
20. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675
21. Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerottini JC, Romero P (2002) Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 23:325-328
22. Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T (2004) Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol 231:112-125
23. Pinilla C, Rubio-Godoy V, Dutoit V, Guillaume P, Simon R, Zhao Y, Houghten RA, Cerottini JC, Romero P, Valmori D (2001) Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res 61:5153-5160
24. Parham P, Brodsky FM (1981) Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277-299
25. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142
26. Houghten RA (1985) General method for the rapid solidphase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82:5131-5135
27. Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, Dunbar PR, Olson K, Dawson SJ, Phillips RE, Jakobsen BK, Bell JI, Sewell AK (2001) The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 276:32786-32792
28. Kersh EN, Kaech SM, Onami TM, Moran M, Wherry EJ, Miceli MC, Ahmed R (2003) TCR signal transduction in antigen-specific memory CD8 T cells. J Immunol 170:5455-5463
29. Krishnan S, Farber DL, Tsokos GC (2003) T cell rewiring in differentiation and disease. J Immunol 171:3325-3331
30. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP (2003) Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9:1377-1382
31. Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM (2003) Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 1:287-294
32. Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, Roederer M, Koup RA, Migueles SA, Gostick E, Wooldridge L, Sewell AK, Connors M, Douek DC (2005) Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 202:1349-1361
33. Maile R, Siler CA, Kerry SE, Midkiff KE, Collins EJ, Frelinger JA (2005) Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immunol 174:619-627
34. Hutchinson SL, Wooldridge L, Tafuro S, Laugel B, Glick M, Boulter JM, Jakobsen BK, Price DA, Sewell AK (2003) The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem 278:24285-24293
35. Slifka MK, Whitton JL (2000) Antigen-specific regulation of T cell-mediated cytokine production. Immunity 12:451-457
36. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 107:4781-4789
37. van Stipdonk MJ, Lemmens EE, Schoenberger SP (2001) Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2:423-429
38. Kaech SM, Ahmed R (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2:415-422
39. Lanzavecchia A, Sallusto F (2002) Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2:982-987
40. Langenkamp A, Casorati G, Garavaglia C, Dellabona P, Lanzavecchia A, Sallusto F (2002) T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 32:2046-2054
41. Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD (2006) In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310:40-52
42. Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355-360
43. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J (2003) Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 9:641-649
44. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A (2006) Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 12:107-116
45. Wilson DB, Pinilla C, Wilson DH, Schroder K, Boggiano C, Judkowski V, Kaye J, Hemmer B, Martin R, Houghten RA (1999) Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. J Immunol 163:6424-6434
46. Hemmer B, Vergelli M, Gran B, Ling N, Conlon P, Pinilla C, Houghten R, McFarland HF, Martin R (1998) Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol 160:3631-3636
47. Nino-Vasquez JJ, Allicotti G, Borras E, Wilson DB, Valmori D, Simon R, Martin R, Pinilla C (2004) A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol 40:1063-1074
48. Hernandez J, Schoeder K, Blondelle SE, Pons FG, Lone YC, Simora A, Langlade-Demoyen P, Wilson DB, Zanetti M (2004) Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur J Immunol 34:2331-2341
49. Jones EY (2005) Favorite flavors of surfaces. Nat Immunol 6:365-366
50. Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NR (1996) T-cell-receptor affinity and thymocyte positive selection. Nature 381:616-620
51. Tanabe M, Karaki S, Takiguchi M, Nakauchi H (1992) Antigen recognition by the T cell receptor is enhanced by CD8 alpha-chain binding to the alpha 3 domain of MHC class I molecules, not by signaling via the cytoplasmic domain of CD8 alpha. Int Immunol 4:147-152
52. Couedel C, Bodinier M, Peyrat MA, Bonneville M, Davodeau F, Lang F (1999) Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities. J Immunol 162:6351-6358
53. Levitsky V, de Campos-Lima PO, Frisan T, Masucci MG (1998) The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J Immunol 161:594-601
54. Wooldridge L, Hutchinson SL, Choi EM, Lissina A, Jones E, Mirza F, Dunbar PR, Price DA, Cerundolo V, Sewell AK (2003) Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 171:6650-6660
55. Wooldridge L, van den Berg HA, Glick M, Gostick E, Laugel B, Hutchinson SL, Milicic A, Brenchley JM, Douek DC, Price DA, Sewell AK (2005) Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 280:27491-27501